	01-12-20	06 Eket No	: ANGIO P-29/500622.20029		
Ŷ	Form PTO-1595 (Rev. 03/01) OMB No. 0651-0027 (exp. 5/31/2002)	ET ET	U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office		
			<u> </u>		
	To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.				
1-00-0t	 Name of conveying party(ies): AngioDynamics, Inc. Queensbury Avenue Queensbury, NY 12804 	2. Name and address Name: Charles N Internal Address:	E		
	Additional name(s) of conveying party(ies) attached? Yes No		m à ë		
	3. Nature of conveyance:		SEC PH OR		
	Assignment and Agreement Merger Security Agreement Change of Name	Street Address:	2033 East Vista Avenue 2 2 SR		
Ĭ	Conveying party: 01/13/2005 Receiving party: 08/20/2005	City: Phoenix	State: AZ Zip: 85020		
	Execution Date: Receiving party: 08/20/2003	Additional name(s) &	address(es) attached? Yes V No		
	4. Application number(s) or patent number(s):				
	If this document is being filed together with a new application, the execution date of the application is:				
	A. Patent Application No.(s)	B. Patent No.(s)			
/114	2006 DBYRNE 00000121 6733489	6,733,489			
L FC	8021 40.00 UP Additional numbers att	ched? Yes ✓ No			
	5. Name and address of party to whom correspondence	6. Total number of a	pplications and patents involved: 1		
\setminus	concerning document should be mailed:				
1	Name: REED SMITH LLP	7. Total fee (37 CFR	R 3.41)\$_40.00		
	Internal Address: c/o Lloyd McAulay	✓ Enclosed			
	E-mail: lmcaulay@reedsmith.com	Authorized to	be charged to deposit account		
	Street Address: 599 Lexington Avenue	8. Deposit account r	number:		
			50-1529		
	City: New York State: NY Zip: 10022-7650	(Attach duplicate copy	of this page if paying by deposit account)		
	DO NOT USE	THIS SPACE			
	9. Statement and signature. To the best of my knowledge and belief, the foregoing in is a true copy of the original document. Lloyd McAulay - Reg. No. 20,423	formation is true and	January 3, 2006		
	Name of Person Signing	Signature	Date		
	Total number of pages including cover	sheet, attachments, and	documents: 3		

Mail documents to be recorded with required cover sheet information to:

MAIL STOP ASSIGNMENT RECORDATION SERVICES Director of the US Patent and Trademark Office P.O. BOX 1450 Alexandria, VA 22313-1450

ASSIGNMENT AND AGREEMENT

WHEREAS, AngioDynamics, Inc., a Delaware corporation having a place of business at 603 Queensbury Avenue, Queensbury, NY 12804 is the owner of the United States Patent listed below as shown by an Assignment recorded at Reel 013334, Frame 0723 on September 26, 2002, and

WHEREAS, AngioDynamics has agreed to assign to Charles Nutting, D.O., for valuable considerations, the receipt of which is hereby acknowledged, a joint ownership in and to the following United States published patent:

<u>Title</u>	Patent No.	Issue Date
Vascular Orientation Marker For Determining The Orientation Of A Blood Vessel	6,733,489	May 11, 2004

WHEREAS, Charles Nutting, D.O. having a residence of 2033 East Vista Avenue, Phoenix, Arizona 85020 desires to obtain such ownership rights in the above-referenced patent.

NOW, THEREFORE, AngioDynamics, Inc., hereby assigns and transfers unto said Charles Nutting, D.O., his successors and assigns a joint ownership in and to said patent and to the invention therein contained, said joint ownership having the rights and effects as if said Assignment recorded on September 26, 2002 had never been executed by Charles Nutting.

NYLIB-264343.1-LMCAULAY 11/23/04 9:22 AM

PATENT REEL: 017435 FRAME: 0305

The parties, AngioDynamics and Charles Nutting, D.O., agree and understand that this transfer of rights from AngioDynamics to Charles Nutting is for the purpose of providing both parties with joint ownership rights in the above-referenced patent as if Charles Nutting had never executed said Assignment dated September 26, 2002.

AngioDynamics agrees that it will maintain a maintenance fee docket on this case and will pay the United States maintenance fees as they come due.

AngioDynamics, Inc.

Dated: 1/13/05 by William Appling
VP, Research

Charles Nutting